Interleukin-6 serum levels in patients with Parkinson's disease.
Several lines of evidence suggest that neuroimmune mechanisms may be involved in the neurodegenerative process of Parkinson's disease (PD). Interleukin-6 (IL-6) is increased in the nigrostriatal region and in the cerebrospinal fluid of patients with PD. IL-6 serum level was evaluated in PD patients. The effects of levodopa treatment and disease severity on IL-6 were also studied. The IL-6 levels were similar between PD patients (treated and not treated) and controls. However, there was a negative correlation of IL-6 levels and the activities of daily living scale (P < 0.05), indicating that patients with more severe disease have higher levels of this cytokine. No correlation involving levodopa treatment and IL-6 serum level was found. The results suggest that only marginal effects of IL-6 occur on the peripheral immune system, and that the role of IL-6 and others neuroimmune factors needs to be well elucidated on PD.
Hofmann
Kerly Wollmeister
KW
Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil.
Schuh
Artur Francisco Schumacher
AF
Saute
Jonas
J
Townsend
Raquel
R
Fricke
Daniele
D
Leke
Renata
R
Souza
Diogo O
DO
Portela
Luis Valmor
LV
Chaves
Márcia Lorena Fagundes
ML
Rieder
Carlos R M
CR
D000203:Activities of Daily Living; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy
D000978:Antiparkinson Agents; D015850:Interleukin-6; D007980:Levodopa